Review



recombinant mouse il 13  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems recombinant mouse il 13
    Recombinant Mouse Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 67 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 13/product/R&D Systems
    Average 95 stars, based on 67 article reviews
    recombinant mouse il 13 - by Bioz Stars, 2026-05
    95/100 stars

    Images



    Similar Products

    94
    MedChemExpress recombinant il 13
    Recombinant Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 13/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant il 13 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant mouse il 13
    Tumor necrosis factor-like ligand 1A (TL1A) expression and secretion increase as asthma progresses. (A) Western blot analysis of TL1A protein expression in the lung tissues in the wild-type and ovalbumin (OVA)-induced model groups. (B) Changes in the cytokine concentrations of TL1A and immunoglobulin E (IgE) in serum over time following the final challenge in cases and controls. (C) Changes in the cytokine concentrations of TL1A, interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 13 <t>(IL-13),</t> and interferon gamma (IFN-γ) in bronchoalveolar lavage fluid (BAL) over time following the final challenge in cases and controls. (D) Schematic summarizing the timeline of the in vivo asthma modeling with different allergen exposure frequencies. (E) Comparison of total cell counts in the BAL in each group for different challenge numbers. (F) Comparison of IL-13 concentrations in BAL changed for different challenge numbers. (G) Representative plots showing changes in eosinophil counts for different challenge numbers. (H) Changes in IgE concentrations in blood samples for different challenge numbers. (I to K) Representative plots showing Masson staining, hematoxylin and eosin (HE) staining, and periodic acid–Schiff (PAS) staining of pulmonary airway tissue in mice for different challenge numbers. (L) Representative plots showing comparison of S100A4 + CD8 + effector memory T (Tem) cell counts for different challenge numbers. (M) Comparison of TL1A expression level in lung tissue samples from each group. (N and O) Comparison of TL1A concentrations in serum/BAL samples in each group. Data are presented as mean ± SD (error bars) from at least 3 independent experiments, with n = 6 mice per group per experiment (A and E to O). Time-course studies (B and C) used n = 6 mice per time point. * P < 0.05 and ** P < 0.01 compared with the respective control groups. Histological scoring and flow cytometry analysis were performed by investigators blinded to the experimental groups.
    Recombinant Mouse Il 13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 13/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant mouse il 13 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant mouse il 13
    Tumor necrosis factor-like ligand 1A (TL1A) expression and secretion increase as asthma progresses. (A) Western blot analysis of TL1A protein expression in the lung tissues in the wild-type and ovalbumin (OVA)-induced model groups. (B) Changes in the cytokine concentrations of TL1A and immunoglobulin E (IgE) in serum over time following the final challenge in cases and controls. (C) Changes in the cytokine concentrations of TL1A, interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 13 <t>(IL-13),</t> and interferon gamma (IFN-γ) in bronchoalveolar lavage fluid (BAL) over time following the final challenge in cases and controls. (D) Schematic summarizing the timeline of the in vivo asthma modeling with different allergen exposure frequencies. (E) Comparison of total cell counts in the BAL in each group for different challenge numbers. (F) Comparison of IL-13 concentrations in BAL changed for different challenge numbers. (G) Representative plots showing changes in eosinophil counts for different challenge numbers. (H) Changes in IgE concentrations in blood samples for different challenge numbers. (I to K) Representative plots showing Masson staining, hematoxylin and eosin (HE) staining, and periodic acid–Schiff (PAS) staining of pulmonary airway tissue in mice for different challenge numbers. (L) Representative plots showing comparison of S100A4 + CD8 + effector memory T (Tem) cell counts for different challenge numbers. (M) Comparison of TL1A expression level in lung tissue samples from each group. (N and O) Comparison of TL1A concentrations in serum/BAL samples in each group. Data are presented as mean ± SD (error bars) from at least 3 independent experiments, with n = 6 mice per group per experiment (A and E to O). Time-course studies (B and C) used n = 6 mice per time point. * P < 0.05 and ** P < 0.01 compared with the respective control groups. Histological scoring and flow cytometry analysis were performed by investigators blinded to the experimental groups.
    Recombinant Mouse Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 13/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    recombinant mouse il 13 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    95
    R&D Systems il 13
    A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus <t>IL-4/IL-13</t> stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.
    Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 13/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    il 13 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant mouse il 13 protein
    A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus <t>IL-4/IL-13</t> stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.
    Recombinant Mouse Il 13 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 13 protein/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    recombinant mouse il 13 protein - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    95
    R&D Systems sterile il 13
    A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus <t>IL-4/IL-13</t> stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.
    Sterile Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sterile il 13/product/R&D Systems
    Average 95 stars, based on 1 article reviews
    sterile il 13 - by Bioz Stars, 2026-05
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress recombinant il13
    A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus <t>IL-4/IL-13</t> stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.
    Recombinant Il13, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il13/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant il13 - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    Tumor necrosis factor-like ligand 1A (TL1A) expression and secretion increase as asthma progresses. (A) Western blot analysis of TL1A protein expression in the lung tissues in the wild-type and ovalbumin (OVA)-induced model groups. (B) Changes in the cytokine concentrations of TL1A and immunoglobulin E (IgE) in serum over time following the final challenge in cases and controls. (C) Changes in the cytokine concentrations of TL1A, interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 13 (IL-13), and interferon gamma (IFN-γ) in bronchoalveolar lavage fluid (BAL) over time following the final challenge in cases and controls. (D) Schematic summarizing the timeline of the in vivo asthma modeling with different allergen exposure frequencies. (E) Comparison of total cell counts in the BAL in each group for different challenge numbers. (F) Comparison of IL-13 concentrations in BAL changed for different challenge numbers. (G) Representative plots showing changes in eosinophil counts for different challenge numbers. (H) Changes in IgE concentrations in blood samples for different challenge numbers. (I to K) Representative plots showing Masson staining, hematoxylin and eosin (HE) staining, and periodic acid–Schiff (PAS) staining of pulmonary airway tissue in mice for different challenge numbers. (L) Representative plots showing comparison of S100A4 + CD8 + effector memory T (Tem) cell counts for different challenge numbers. (M) Comparison of TL1A expression level in lung tissue samples from each group. (N and O) Comparison of TL1A concentrations in serum/BAL samples in each group. Data are presented as mean ± SD (error bars) from at least 3 independent experiments, with n = 6 mice per group per experiment (A and E to O). Time-course studies (B and C) used n = 6 mice per time point. * P < 0.05 and ** P < 0.01 compared with the respective control groups. Histological scoring and flow cytometry analysis were performed by investigators blinded to the experimental groups.

    Journal: Research

    Article Title: Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma

    doi: 10.34133/research.1190

    Figure Lengend Snippet: Tumor necrosis factor-like ligand 1A (TL1A) expression and secretion increase as asthma progresses. (A) Western blot analysis of TL1A protein expression in the lung tissues in the wild-type and ovalbumin (OVA)-induced model groups. (B) Changes in the cytokine concentrations of TL1A and immunoglobulin E (IgE) in serum over time following the final challenge in cases and controls. (C) Changes in the cytokine concentrations of TL1A, interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 13 (IL-13), and interferon gamma (IFN-γ) in bronchoalveolar lavage fluid (BAL) over time following the final challenge in cases and controls. (D) Schematic summarizing the timeline of the in vivo asthma modeling with different allergen exposure frequencies. (E) Comparison of total cell counts in the BAL in each group for different challenge numbers. (F) Comparison of IL-13 concentrations in BAL changed for different challenge numbers. (G) Representative plots showing changes in eosinophil counts for different challenge numbers. (H) Changes in IgE concentrations in blood samples for different challenge numbers. (I to K) Representative plots showing Masson staining, hematoxylin and eosin (HE) staining, and periodic acid–Schiff (PAS) staining of pulmonary airway tissue in mice for different challenge numbers. (L) Representative plots showing comparison of S100A4 + CD8 + effector memory T (Tem) cell counts for different challenge numbers. (M) Comparison of TL1A expression level in lung tissue samples from each group. (N and O) Comparison of TL1A concentrations in serum/BAL samples in each group. Data are presented as mean ± SD (error bars) from at least 3 independent experiments, with n = 6 mice per group per experiment (A and E to O). Time-course studies (B and C) used n = 6 mice per time point. * P < 0.05 and ** P < 0.01 compared with the respective control groups. Histological scoring and flow cytometry analysis were performed by investigators blinded to the experimental groups.

    Article Snippet: The recombinant proteins, small-molecular compounds, or inhibitors were purchased as indicated: recombinant mouse IL-13, IL-33, and TSLP protein (MCE); recombinant human IL-2, IL-4, TNF-α, and IFN-γ protein (Abbkine); poly(I:C) (Selleck); lipopolysaccharide (Sigma-Aldrich); IL-1β (Thermo Fisher); and small-molecule inhibitors BAY11-7082, LY294002, PD98059, SB203580, and SP600125 (Selleck).

    Techniques: Expressing, Western Blot, In Vivo, Comparison, Staining, Control, Flow Cytometry

    Myeloid-cell-specific Tnfsf15 -knockout resulted in the attenuation of allergic airway inflammation. (A) Myeloid-cell-specific Tnfsf15 -knockout strategy. (B) Genotyping was confirmed using tail DNA genomic polymerase chain reaction. (C) Immunomagnetic bead sorting was used to isolate F4/80 + cells, and the expression level of tumor necrosis factor-like ligand 1A (TL1A) was quantified using Western blotting. (D to G) Representative plots showing the proportions of 4 major types of immune cells (macrophages, CD8 + T cells, CD4 + T cells, and B cells) infiltrating the lung tissues in each group. (H) Representative hematoxylin and eosin (HE) staining among the different groups and quantification of the airway inflammation score. Black scale bar, 50 µm. (I) Representative periodic acid–Schiff (PAS) staining among the different groups and quantification of the airway mucus score. (J) Representative Masson’s trichrome staining among the different groups and quantification of the collagen volume fraction. (K and L) Lung eosinophil or neutrophil counts, as determined by flow cytometry. (M) Total cell counts in bronchoalveolar lavage fluid (BAL). (N) Concentrations of interleukin 4 (IL-4) in BAL. (O) Concentrations of interleukin 13 (IL-13) in BAL. Data are presented as mean ± SD. Experiments were repeated 3 times with n = 6 to 8 mice per group per experiment. Cell sorting and Western blot (C) used pooled cells from n = 4 mice. Flow cytometry analyses (D to G and K) and histological scoring (H to J) were performed by investigators blinded to genotype and treatment. * P < 0.05 and ** P < 0.01 compared with the respective groups.

    Journal: Research

    Article Title: Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma

    doi: 10.34133/research.1190

    Figure Lengend Snippet: Myeloid-cell-specific Tnfsf15 -knockout resulted in the attenuation of allergic airway inflammation. (A) Myeloid-cell-specific Tnfsf15 -knockout strategy. (B) Genotyping was confirmed using tail DNA genomic polymerase chain reaction. (C) Immunomagnetic bead sorting was used to isolate F4/80 + cells, and the expression level of tumor necrosis factor-like ligand 1A (TL1A) was quantified using Western blotting. (D to G) Representative plots showing the proportions of 4 major types of immune cells (macrophages, CD8 + T cells, CD4 + T cells, and B cells) infiltrating the lung tissues in each group. (H) Representative hematoxylin and eosin (HE) staining among the different groups and quantification of the airway inflammation score. Black scale bar, 50 µm. (I) Representative periodic acid–Schiff (PAS) staining among the different groups and quantification of the airway mucus score. (J) Representative Masson’s trichrome staining among the different groups and quantification of the collagen volume fraction. (K and L) Lung eosinophil or neutrophil counts, as determined by flow cytometry. (M) Total cell counts in bronchoalveolar lavage fluid (BAL). (N) Concentrations of interleukin 4 (IL-4) in BAL. (O) Concentrations of interleukin 13 (IL-13) in BAL. Data are presented as mean ± SD. Experiments were repeated 3 times with n = 6 to 8 mice per group per experiment. Cell sorting and Western blot (C) used pooled cells from n = 4 mice. Flow cytometry analyses (D to G and K) and histological scoring (H to J) were performed by investigators blinded to genotype and treatment. * P < 0.05 and ** P < 0.01 compared with the respective groups.

    Article Snippet: The recombinant proteins, small-molecular compounds, or inhibitors were purchased as indicated: recombinant mouse IL-13, IL-33, and TSLP protein (MCE); recombinant human IL-2, IL-4, TNF-α, and IFN-γ protein (Abbkine); poly(I:C) (Selleck); lipopolysaccharide (Sigma-Aldrich); IL-1β (Thermo Fisher); and small-molecule inhibitors BAY11-7082, LY294002, PD98059, SB203580, and SP600125 (Selleck).

    Techniques: Knock-Out, Polymerase Chain Reaction, Expressing, Western Blot, Staining, Flow Cytometry, FACS

    Identification of C-C motif chemokine ligand 8 (CCL8) as the key link in the tumor necrosis factor-like ligand 1A (TL1A)-induced allergic inflammatory response. (A) Heatmap showing changes in proallergic chemokine expression levels after gene knockdown. (B) Relative gene expression of CCL8 in lung tissue, quantified using polymerase chain reaction (PCR). (C) Relative gene expression of CCL8 in sorted F4/80 + cell groups in lung tissue, quantified using PCR. (D) CCL8 concentration in bronchoalveolar lavage fluid (BAL) measured using enzyme-linked immunosorbent assay (ELISA). (E) Relative gene expression of CCL8 in lung tissue, quantified using PCR in Tnfsf15 -knockout (KO) mice. (F) CCL8 concentration in BAL measured using ELISA in Tnfsf15 -KO mice. (G) CCL8 expression in the lung tissue of Tnfsf15 transgenic and nontransgenic mice. (H) The correlation between TL1A and CCL8 expression in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort (based on GSE76262 ). (I) Schematic of the murine ovalbumin-induced asthma models following recombinant TL1A or anti-C-C motif chemokine receptor 8 (anti-CCR8) intervention. (J) Hematoxylin and eosin (HE) staining of lung tissue after allergen challenge and recombinant TL1A (rTL1A) or anti-CCR8 interventions. Black scale bar, 50 µm. (K) Total cell numbers in BAL samples. (L to N) Concentrations of CCL8, interleukin 4 (IL-4), and interleukin 13 (IL-13) in BAL samples from the different groups. Data are presented as mean ± SD from at least 2 independent experiments, with n = 5 to 6 mice per group per experiment. PCR, ELISA, and histological assessments were conducted by researchers blinded to treatment groups. Public dataset correlation (H) used n = samples from the GSE76262 dataset. * P < 0.05 and ** P < 0.01 compared with the respective groups.

    Journal: Research

    Article Title: Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma

    doi: 10.34133/research.1190

    Figure Lengend Snippet: Identification of C-C motif chemokine ligand 8 (CCL8) as the key link in the tumor necrosis factor-like ligand 1A (TL1A)-induced allergic inflammatory response. (A) Heatmap showing changes in proallergic chemokine expression levels after gene knockdown. (B) Relative gene expression of CCL8 in lung tissue, quantified using polymerase chain reaction (PCR). (C) Relative gene expression of CCL8 in sorted F4/80 + cell groups in lung tissue, quantified using PCR. (D) CCL8 concentration in bronchoalveolar lavage fluid (BAL) measured using enzyme-linked immunosorbent assay (ELISA). (E) Relative gene expression of CCL8 in lung tissue, quantified using PCR in Tnfsf15 -knockout (KO) mice. (F) CCL8 concentration in BAL measured using ELISA in Tnfsf15 -KO mice. (G) CCL8 expression in the lung tissue of Tnfsf15 transgenic and nontransgenic mice. (H) The correlation between TL1A and CCL8 expression in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort (based on GSE76262 ). (I) Schematic of the murine ovalbumin-induced asthma models following recombinant TL1A or anti-C-C motif chemokine receptor 8 (anti-CCR8) intervention. (J) Hematoxylin and eosin (HE) staining of lung tissue after allergen challenge and recombinant TL1A (rTL1A) or anti-CCR8 interventions. Black scale bar, 50 µm. (K) Total cell numbers in BAL samples. (L to N) Concentrations of CCL8, interleukin 4 (IL-4), and interleukin 13 (IL-13) in BAL samples from the different groups. Data are presented as mean ± SD from at least 2 independent experiments, with n = 5 to 6 mice per group per experiment. PCR, ELISA, and histological assessments were conducted by researchers blinded to treatment groups. Public dataset correlation (H) used n = samples from the GSE76262 dataset. * P < 0.05 and ** P < 0.01 compared with the respective groups.

    Article Snippet: The recombinant proteins, small-molecular compounds, or inhibitors were purchased as indicated: recombinant mouse IL-13, IL-33, and TSLP protein (MCE); recombinant human IL-2, IL-4, TNF-α, and IFN-γ protein (Abbkine); poly(I:C) (Selleck); lipopolysaccharide (Sigma-Aldrich); IL-1β (Thermo Fisher); and small-molecule inhibitors BAY11-7082, LY294002, PD98059, SB203580, and SP600125 (Selleck).

    Techniques: Expressing, Knockdown, Gene Expression, Polymerase Chain Reaction, Concentration Assay, Enzyme-linked Immunosorbent Assay, Knock-Out, Transgenic Assay, Recombinant, Staining

    A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus IL-4/IL-13 stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.

    Journal: bioRxiv

    Article Title: Discovery of metabolites produced by reactions between central carbon metabolites and cysteine that mark inflammatory macrophages

    doi: 10.64898/2026.03.18.712640

    Figure Lengend Snippet: A. volcano plot of discovery metabolomics comparing BMDMs that stimulated with LPS/IFNγ (at 48h post stimulation) versus unstimulated. Colored points indicate parent feature (blue circle) and 34 S isotope peak candidates (purple circle) with orange line indicated parent-isotope pair. Only parent feature that meet > 2.5-fold change and significance < 0.05 are labeled. Citrulline (green triangle) (and its isotope peaks and MS adducts) are labeled as a positive control for classical activation induced metabolites. Each point represents the mean of n = 3 biological replicates. B. volcano plot of metabolomic features in parallel cells cultured in media containing unlabeled cystine versus 3,3- 13 C 2 -L-cystine. Pairs with significant isotopic shift are colored blue and red. Pairs that match parent features in (A) are labeled with m/z values. Each point represents the mean, n = 3 biological replicates. C. Extracted ion chromatograms (EICs) for major cysteine adducts in LPS/IFNγ-stimulated BMDM (red) compared to in unstimulated BMDMs (blue). Identified molecular formulas based on isotopic distribution and exact mass are labeled. Formulas shown in red do not correspond to known mammalian metabolites. D-F. The changes in major cysteine-adducts in BMDMs over a time course of LPS/IFNγ stimulation (blue) versus IL-4/IL-13 stimulation (green). Mean +/- standard deviation, n= 3 biological replicates.

    Article Snippet: For alternative activation, BMDMs were treated with with 20 ng ml −1 IL-4 (cat. no. 404-ML, R&D Systems) and 20 ng ml −1 IL-13 (cat. no. 413-ML-005, R&D Systems).

    Techniques: Labeling, Positive Control, Activation Assay, Metabolomic, Cell Culture, Standard Deviation